Breaking Finance News

A report released today by Societe Generale about Bayer (ETR:BAYN) ups the target price to 105.00EUR

Societe Generale bumped up the target of Bayer (ETR:BAYN) to 105.00EUR indicating a possible upside of 0.15%.

On 9/20/2016, S&P Capital IQ released a statement on Bayer (ETR:BAYN) raised the target price from 0.00EUR to 120.00EUR. At the time, this indicated a possible upside of 0.30%.

Only yesterday Bayer (ETR:BAYN) traded 0.00% even at 91.46EUR. The company’s 50-day moving average is 0.04EUR and its 200-day moving average is 0.03EUR. The last closing price is up -4.07% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the date range. Trading volume was down over the average, with 0 shares of BAYN changing hands under the typical 215

Recent Performance Chart

Bayer (ETR:BAYN)

Bayer has a one year low of 0.03EUR and a one year high of 0.04EUR BAYN’s total market value is presently 0 EUR.

General Company Details For Bayer (ETR:BAYN)

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.